Back to Archived News
Microdroplet BOTOX Technology by Dr. Kenneth Steinsapir Recognized By U.S. Patent Office
Tuesday, October 05, 2010
Innovative Botulinum Toxin (BOTOX®, Dysport®, Xeomin®) Treatment Capitalizes BOTOX Benefits, Reduces Side Effects
Los Angeles, CA -- The patent application for Microdroplet™ botulinum toxin, a treatment that improves facial features without detracting from facial expressiveness, has been allowed to inventor Dr. Kenneth D. Steinsapir, M.D. on September 2, 2010. The United States Patent and Trademark Office approved the invention as detailed in U.S. patent application 11/429,057 in a move that validates the research and utility behind this medical technology. The actual patent will issue shortly.
Microdroplet™ botulinum toxin (BOTOX®, Dysport®, Xeomin®) is a precise method of elevating the eyebrow position and softening overactive muscles to enhance one’s facial appearance. Whereas standard botulinum toxin treatments involve injecting larger amounts of botulinum toxin in relatively few places, Microdroplet™ botulinum toxin relies on tiny injection volumes of botulinum toxin dissolved in microdroplets. This controlled placement avoids the most common BOTOX® side effects of the “frozen forehead” or “bat face.” Because of the retained ability to express emotion, Microdroplet™ BOTOX® is popular among actors, actresses, and executives.
Dr. Steinsapir trained with the inventor of BOTOX® and has been providing BOTOX® services since 1988. He observed that while standard BOTOX® treatments relax the facial features and improve facial lines, they can also cause a fall in the eyebrow position and “freeze” the forehead.
“The Microdroplet botulinum toxin patent recognition speaks for the rising awareness that we should always strive for natural results,” says Dr. Steinsapir. “This technique does not simply paralyze the muscles in your forehead, and in fact it is not applied to the forehead at all. Instead the eyebrow and crows feet areas are treated. Since this weakens the eyebrow depressors, the forehead muscles don’t have to work as hard, and the forehead lines and brow placement improve without causing the upper eyelid to fall. It’s like a forehead lift without surgery.”
For more information about the Microdroplet™ botulinum toxin patent application, visit www.lidlift.com or contact Steinsapir@lidlift.com.
About Kenneth D. Steinsapir, M.D., Inc.
Kenneth D. Steinsapir, M.D., Inc. is located in Los Angeles, California. Dr. Steinsapir is a board certified oculofacial and cosmetic surgeon and associate clinical professor of ophthalmology at UCLA,emphasizing minimally invasive treatments for natural results.
Back to Archived News